Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 10, 2011, Pages 4117-4122

  Zhang, Danfang ^a,b   Hedlund, Eva Maria E ^a   Lim, Sharon ^a   Chen, Fang ^a   Zhang, Yin ^a   Sun, Baocun ^b   Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Anemia; Angiogenesis; Angiogenic factors; Antiangiogenic therapy; Cancer therapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; SUNITINIB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HEMATOPOIESIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; HEMATOPOIESIS; MELANOMA, EXPERIMENTAL; MICE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 79952769787     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016220108     Document Type: Article

References (23)

1. Cao Y, Langer R (2010) Optimizing the delivery of cancer drugs that block angiogenesis. Sci Translat Med 2:15ps13.
2. Cao Y, Zhong W, Sun Y (2009) Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 19:338-343.
3. Sarmiento R, D'Andrea MR, Cacciamani F, Salerno F, Gasparini G (2009) Antiangiogenic therapies in breast cancer. Curr Opin Investig Drugs 10:1334-1345.
4. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
5. Motzer RJ, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
6. Xue Y, et al. (2008) Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA 105: 18513-18518.
7. Cao Y (2010) Off-tumor target-beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol 7:604-608.
8. Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862-871.
9. Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 9:13-21. (Pubitemid 28125759)
10. Powis G (1983) Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab Rev 14:1145-1163.
11. Egorin MJ (2008) Population pharmacokinetc/pharmacodynamic modeling of paclitaxel and carboplatin in ovarian cancer. Clin Cancer Res, 14:2517, author reply 2517-2518.
12. Wong AK, et al. (2001) Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 98:7481-7486. (Pubitemid 32567974)
13. Xue Y, Chen F, Zhang D, Lim S, Cao Y (2009) Tumor-derived VEGF modulates hematopoiesis. J Angiogenes Res 1:9.
14. Kumar R, et al. (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101:1717-1723.
15. Hedlund EM, Hosaka K, Zhong Z, Cao R, Cao Y (2009) Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci USA 106:17505-17510.
16. Eriksson A, et al. (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/ VEGF heterodimers. Cancer Cell 1:99-108. (Pubitemid 41039180)
17. Cao R, et al. (2010) VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancerassociated retinopathy. Proc Natl Acad Sci USA 107:856-861.
18. Hayes DF, et al.; Cancer and Leukemia Group B (CALGB) Investigators (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506.
19. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
20. Ledford H (2008) Drug markers questioned. Nature 452:510-511.
21. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795. (Pubitemid 46912024)
22. Todorov P, et al. (1996) Characterization of a cancer cachectic factor. Nature 379:739-742. (Pubitemid 26061738)
23. Björndahl M, et al. (2005) Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102:15593-15598. (Pubitemid 41528101)